| Literature DB >> 32330423 |
Deepak Bararia1, Johannes A Hildebrand1, Sebastian Stolz2, Sarah Haebe2, Stefan Alig2, Christopher P Trevisani3, Francisco Osorio-Barrios4, Michael D Bartoschek5, Michael Mentz2, Alessandro Pastore6, Erik Gaitzsch1, Michael Heide1, Vindi Jurinovic7, Katharina Rautter8, Jay Gunawardana9, Muhammed B Sabdia9, Monika Szczepanowski10, Julia Richter10, Wolfram Klapper10, Abner Louissaint11, Christina Ludwig12, Sebastian Bultmann5, Heinrich Leonhardt5, Sebastian Eustermann13, Karl-Peter Hopfner13, Wolfgang Hiddemann1, Michael von Bergwelt-Baildon1, Christian Steidl14, Robert Kridel14, Joshua W D Tobin9, Maher K Gandhi9, David M Weinstock3, Marc Schmidt-Supprian15, Menyhárt B Sárosi16, Martina Rudelius17, Verena Passerini1, Josef Mautner18, Oliver Weigert19.
Abstract
Tumor cells orchestrate their microenvironment. Here, we provide biochemical, structural, functional, and clinical evidence that Cathepsin S (CTSS) alterations induce a tumor-promoting immune microenvironment in follicular lymphoma (FL). We found CTSS mutations at Y132 in 6% of FL (19/305). Another 13% (37/286) had CTSS amplification, which was associated with higher CTSS expression. CTSS Y132 mutations lead to accelerated autocatalytic conversion from an enzymatically inactive profrom to active CTSS and increased substrate cleavage, including CD74, which regulates major histocompatibility complex class II (MHC class II)-restricted antigen presentation. Lymphoma cells with hyperactive CTSS more efficiently activated antigen-specific CD4+ T cells in vitro. Tumors with hyperactive CTSS showed increased CD4+ T cell infiltration and proinflammatory cytokine perturbation in a mouse model and in human FLs. In mice, this CTSS-induced immune microenvironment promoted tumor growth. Clinically, patients with CTSS-hyperactive FL had better treatment outcomes with standard immunochemotherapies, indicating that these immunosuppressive regimens target both the lymphoma cells and the tumor-promoting immune microenvironment.Entities:
Keywords: T cell activation; antigen processing and presentation; cathepsin S; cysteine-protease; follicular lymphoma; immune microenvironment
Mesh:
Substances:
Year: 2020 PMID: 32330423 DOI: 10.1016/j.celrep.2020.107522
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423